Floatz logo

Alpelisib

Sickle Cell Anemia

National Heart, Lung, and Blood Institute (NHLBI)Small moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Sickle Cell Anemia cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Sildenafil
The Baruch Padeh Medical Center, Poriya
Phase 4BB
L-Nmma
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2BB
AMLODIPINE
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2BB
Campath
Columbia University
Phase 2/3BB

View all 40 →

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →